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Abstract
The convergence of US GAAP and IFRS has been significant for the US Financial
Accounting Standards Board (FASB) and the International Accounting Standards Board (IASB)
over the decade. Due to major differences such as with the consolidation model and the special
entities (i.e. Research and Development), there are concerns of how the convergence will affect
the accounting practice. The US GAAP is known to have more industry-based details than the
IFRS, and so it is essential to know what kind of issues lie from industry to industry. Here, our
focus is within the life sciences. More specifically, this paper examines the financial statements
of the top 10 firms in the pharmaceutical industry for both the United States and Europe. By
analyzing and comparing the documentation, we can see the similarities and differences of using
either the GAAP or IFRS. With these results, the impact of the convergence of the US GAAP
and IFRS on the industry and as a whole will be concluded.
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Introduction
Public Accounting has faced many obstacles with the two different accounting standards
used in the United States and Internationally. With different standards, two oversight groups
were established, Financial Accounting Standards Board (FASB) and the International
Accounting Standards Board (IASB). Thus, in September 2002 the IASB and the FASB agreed
to work together, in consultation with other national and regional bodies, to remove the
differences between international standards and US GAAP. This decision was embodied in a
Memorandum of Understanding (MoU) between the boards known as the Norwalk Agreement.1
The FASB’s mission is to improve U.S. financial accounting standards for the benefit of
present and potential investors, lenders, donors, creditors, and other users of financial statements.
The FASB believes that pursuing convergence – making global accounting standards as similar
as possible – is fully consistent with that mission. Investors, companies, auditors, and other
participants in the U.S. financial reporting system should benefit from the increased
comparability that would result from internationally converged accounting standards. More
comparable standards would reduce costs to both users and preparers of financial statements and
make worldwide capital markets more efficient.2
On the other hand, the IASB’s goal is to develop a single set of high quality,
understandable, enforceable and globally accepted International Financial Reporting Standards
(IFRSs) through its standard-setting body, the International Accounting Standards Board (IASB),
as well as, promote the use and rigorous application of those standards.3
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"Convergence between IFRSs and US GAAP." IFRS. <http://www.ifrs.org/Use-around-the-world/Globalconvergence/Convergence-with-US-GAAP/Pages/Convergence-with-US-GAAP.aspx>.
2
"International Convergence of Accounting Standards - Overview." FASB. 25 Apr. 2014
<http://www.fasb.org/jsp/FASB/Page/SectionPage%26cid%3D1176156245663>.
3
"About the IFRS Foundation and the IASB." IFRS. <http://www.ifrs.org/The-organisation/Pages/IFRSFoundation-and-the-IASB.aspx>.

2

Convergence will move U.S. accounting from a detailed, rules-based approach to a more
principles-based approach, and every aspect of operations will be affected. This makes the rules
more difficult to apply initially, because it offers few clear-cut answers to accounting questions.
This difference will require companies to more strongly focus on the definition of their
accounting policies, resulting in increased transparency of financial reporting and improved
consistency across businesses, industries and countries.4
Strict guidelines found under GAAP will no longer be followed if there is a change to
IFRS. Thus, allowing organizations to their revenue recognition policies to make their financial
statements look better. This will be good because of the discretion that managers can use to
better recognize their revenues within their company. With more choice comes less
comparability even between companies with similar operations. The disclosures under IFRS will
help maintain some of the comparability because managers have to explain why they choose a
particular method of revenue recognition.
Why is this topic important? Many factors including Globalization, the Sarbanes-Oxley
Act, the SEC adoption of international standards, and the economic and financial meltdown in
recent years have been exerting pressure on a number of countries, including the United States,
to eliminate the gap between the International Financial Reporting Standards (IFRS) and the U.S.
Generally Accepted Accounting Principles (GAAP).5 And it is a necessity to analyze the impact
these changes may have on current and future employees in the accounting industry.
Are we in need of a convergence of IFRS and GAAP? What will be the impact of the
decided change to IFRS on major public accounting firms? What actions will these firms take to
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"What companies need to know about the impending switch to IFRS." Smart Business. 7 July 2011.
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adjust to the change? How will this affect public accounting within the next 5 years? More
precisely, when looking at the pharmaceutical industry, what kind of impact could we expect for
other industries? This paper will explain the differences between GAAP and IFRS, in order to
understand why there is differences in revenue recognition and intangible assets, which are two
major changes to occur in the pharmaceutical industry.
GAAP vs IFRS
The overarching difference between the two accounting standards is US GAAP is rule
based and IFRS is principle based. The difference between these two approaches is on the
methodology to assess an accounting treatment. Under U.S. GAAP, the research is more focused
on the literature whereas under IFRS, the review of the facts pattern is more thorough. However,
the professional judgment is not a new concept in the U.S. environment. The SEC is addressing
this topic in order to find the right balance between the “educated” professional judgment, that is
acceptable, and the “guessed” professional judgment.6
The IFRS project is the first step at trying to internationalize global accounting standards
to be used by all companies both inside and outside the United States. Presently, United
Kingdom companies are governed by IFRS issued by the International Accounting Standards
Board (IASB). Effective in 2005, all companies listed on European stock exchanges
(approximately 8,000) adopted IASB standards. As of 2010, approximately 120 countries
required or allowed their companies to adopt the new international standards including the U.K.,
Australia, Japan, and New Zealand. Chile and South Korea adopted IFRS in 2009, Brazil in
2010, Canada and India in 2011, and Mexico adopted starting in 2012. Japan will decide in 2012
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"Is IFRS That Different From U.S. GAAP?" AICPA | www.IFRS.com. 16 June 2008.
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about an adoption in 2015 or 2016. A total of more than 12,000 companies are now using IFRS
worldwide.7
With such a project, there have been many supporters. For example, CEO of Speed Tax,
Anton Donde, stated I support the creation of a single set of global accounting standards -- and
truly believe IFRS is way overdue. A single set of standards will not only simplify the way
companies conduct themselves, but encourage 100 percent adoption of ethical behavior. In
addition, any time somewhat-disparate regulatory bodies can come together for a common cause
-- even though the rules may be somewhat complicated to follow in the short term -- the public
will appreciate the effort because it builds long-term trust and a much stronger economy.8
Pharmaceutical Industry Analysis
The pharmaceutical industry has four major processes in its value chain — discovery,
development, manufacturing, and marketing and sales. Each of these processes is vital for the
success of a pharmaceutical company. In some cases, a large, vertically-integrated
pharmaceutical firm carries out a lot of these functions. Sometimes, however, certain activities
are contracted or outsourced to other firms. The trend of outsourcing has grown over the past
decade. Outsourcing of drug development to contract research organizations (CROs), or
manufacturing to contract manufacturing organizations (CMOs), is common and has led to the
development of a new industry known as contract research and manufacturing services
(CRAMS). The pharmaceutical industry environment is complex, and requires pharmaceutical
companies to balance various aspects of their business. The Pharmaceutical industry is
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characterized by significant research and development spends, heavy regulations surrounding
research, clinical trials, drug manufacture and sales and marketing practices and pricing.9
Below is a list of global pharmaceutical companies and the accounting standard that they
follow:
Company
Actelion
Amgen
AstraZeneca
Allergan
Bristol Myers Squibb
Celgene
Elan Corp.
Eli Lilly

Standard Used
US GAAP
US GAAP
IFRS
US GAAP
US GAAP
US GAAP
IFRS
US GAAP

Company
Genetech, Inc.
GlaxoSmithKline
Roche
Johnson & Johnson
Merck & Co., Inc.
Novartis
Pfizer
Sanofi-Aventis

Standard Used
US GAAP
IFRS
IFRS
US GAAP
US GAAP
IFRS
US GAAP
IFRS

Using this information, the annual reports for the top pharmaceutical companies within the US
and Europe were analyzed for differences between revenue recognition and intangible assets. As
these are two important areas that have shown major variances, it is important to see the impact
of these areas between the different companies.
Johnson & Johnson10
The Company recognizes revenue from product sales when goods are shipped or
delivered, and title and risk of loss pass to the customer. Provisions for certain rebates, sales
incentives, trade promotions, coupons, product returns and discounts to customers are accounted
for as reductions in sales in the same period the related sales are recorded.
Product discounts granted are based on the terms of arrangements with direct, indirect and other
market participants, as well as market conditions, including prices charged by competitors.
Rebates, the largest being the Medicaid rebate provision, are estimated based on contractual

9

"Accounting and Auditing Update" KPMG. July 2010.
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terms, historical experience, trend analysis and projected market conditions in the various
markets served. The Company evaluates market conditions for products or groups of products
primarily through the analysis of wholesaler and other third-party sell-through and market
research data, as well as internally generated information.
Sales returns are generally estimated and recorded based on historical sales and returns
information. Products that exhibit unusual sales or return patterns due to dating, competition or
other marketing matters are specifically investigated and analyzed as part of the accounting for
sales return accruals. Sales returns allowances represent a reserve for products that may be
returned due to expiration, destruction in the field, or in specific areas, product recall. The
returns reserve is based on historical return trends by product and by market as a percent to gross
sales. In accordance with the Company’s accounting policies, the Company generally issues
credit to customers for returned goods. The Company’s sales returns reserves are accounted for
in accordance with the U.S. GAAP guidance for revenue recognition when right of return exists.
Sales returns reserves are recorded at full sales value. Sales returns in the Consumer and
Pharmaceutical segments are almost exclusively not resalable.
Promotional programs, such as product listing allowances and cooperative advertising
arrangements, are recorded in the year incurred. Continuing promotional programs include
coupons and volume-based sales incentive programs. The redemption cost of consumer coupons
is based on historical redemption experience by product and value. Volume-based incentive
programs are based on estimated sales volumes for the incentive period and are recorded as
products are sold. The Company also earns service revenue for co-promotion of certain products.
For all years presented, service revenues were less than 2% of total revenues and are included in
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sales to customers. These arrangements are evaluated to determine the appropriate amounts to be
deferred.
During the fiscal first quarter of 2013, the Company adopted the Financial Accounting
Standards Board (FASB) guidance and amendments related to testing indefinite-lived intangible
assets for impairment. Under the amendments in this update, an entity has the option to first
assess qualitative factors to determine whether the existence of events or circumstances indicates
that it is more likely than not that the indefinite-lived intangible asset is impaired. If, after
assessing the totality of events and circumstances, an entity concludes that it is not more likely
than not that the indefinite-lived intangible asset is impaired, then the entity is not required to
determine the fair value. However, if an entity concludes otherwise, then it is required to
determine the fair value of the indefinite-lived intangible asset and perform the quantitative
impairment test. An entity also has the option to bypass the qualitative assessment for any
indefinite-lived intangible asset in any period and proceed directly to performing the quantitative
impairment test. This update became effective for annual and interim impairment tests performed
for fiscal years beginning after September 15, 2012. The adoption of this standard did not have a
material impact on the Company’s results of operations, cash flows or financial position.
Pfizer11
Pfizer records revenues from product sales when the goods are shipped and title passes to
the customer. At the time of sale, we also record estimates for a variety of sales deductions, such
as sales rebates, discounts and incentives, and product returns. When we cannot reasonably
estimate the amount of future product returns and/or other sales deductions, we record revenues
when the risk of product return and/or additional sales deductions has been substantially

11
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eliminated. We record sales of certain of our vaccines to the U.S. government as part of the
Pediatric Vaccine Stockpile program; these rules require that for fixed commitments made by the
U.S. government, we record revenues when risk of ownership for the completed product has
been passed to the U.S. government. There are no specific performance obligations associated
with products sold under this program.
These acquired assets are recorded at cost. Intangible assets with finite lives are
amortized on a straight-line basis over their estimated useful lives. Intangible assets with
indefinite lives that are associated with marketed products are not amortized until a useful life
can be determined. Intangible assets associated with IPR&D projects are not amortized until
approval is obtained in a major market, typically either the U.S. or the European Union (EU), or
in a series of other countries, subject to certain specified conditions and management judgment.
The useful life of an amortizing asset generally is determined by identifying the period in which
substantially all of the cash flows are expected to be generated.
Merck & Co., Inc.12
Revenues from sales of products are recognized at the time of delivery when title and risk
of loss passes to the customer. Recognition of revenue also requires reasonable assurance of
collection of sales proceeds and completion of all performance obligations. Domestically, sales
discounts are issued to customers as direct discounts at the point-of-sale or indirectly through an
intermediary wholesaler, known as chargebacks, or indirectly in the form of rebates.
Additionally, sales are generally made with a limited right of return under certain conditions.
Revenues are recorded net of provisions for sales discounts and returns, which are established at

12

Merck & Co., Inc. Annual report 2013. < http://www.merck.com/investors/financials/annual-reports/home.html>

9

the time of sale. In addition, revenues are recorded net of time value of money discounts if
collection of accounts receivable is expected to be in excess of one year.
Acquired intangibles include products and product rights, trade names and patents, which
are recorded at fair value, assigned an estimated useful life, and are amortized primarily on a
straight-line basis over their estimated useful lives ranging from 3 to 40 years. Merck
periodically evaluates whether current facts or circumstances indicate that the carrying values of
its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an
estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is
compared to the carrying value to determine whether an impairment exists. If the asset is
determined to be impaired, the loss is measured based on the difference between the carrying
value of the intangible asset and its fair value, which is determined based on the net present value
of estimated future cash flows.
Novartis13
Revenue is recognized on the sale of Novartis Group products and services and recorded
as "Net sales" in the consolidated income statement when there is persuasive evidence that a
sales arrangement exists, title and risks and rewards for the products are transferred to the
customer, the price is determinable and collectability is reasonably assured. When contracts
contain customer acceptance provisions, sales are recognized upon the satisfaction of acceptance
criteria. For surgical equipment this occurs when title and risk and rewards are transferred after
installation and any required training has been completed. For surgical equipment leased to
customers, revenue representing the net present value of the minimum lease payments is
recognized at the commencement of the lease term if the lease term is for the major part of the

13
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economic life of the asset or if the payments represent substantially most of its fair value, even if
the legal ownership is not transferred. If products are stockpiled at the request of the customer,
revenue is only recognized once the products have been inspected and accepted by the customer
and there is no right of return or replenishment on product expiry and cost of storage will be paid
by the customer on normal commercial terms.
Cash discounts are offered to customers to encourage prompt payment and are recorded
as revenue deductions. Wholesaler shelf-inventory adjustments are granted to customers based
on the existing inventory of a product at the time of decreases in the invoice or contract price of a
product or at the point of sale if a price decline is reasonably estimable. When there is historical
experience of Novartis agreeing to customer returns or Novartis can otherwise reasonably
estimate expected future returns, a provision is recorded for estimated sales returns. In doing so
the estimated rate of return is applied, determined based on historical experience of customer
returns or considering any other relevant factors. This is applied to the amounts invoiced also
considering the amount of returned products to be destroyed versus products that can be placed
back in inventory for resale. Where shipments are made on a re-sale or return basis, without
sufficient historical experience for estimating sales returns, revenue is only recorded when there
is evidence of consumption or when the right of return has expired.
Intangible assets available for use are amortized over their estimated useful lives on a
straight-line basis and evaluated for potential impairment whenever facts and circumstances
indicate that their carrying value may not be recoverable.
Acquired research and development intangible assets, which are still under development
and have accordingly not yet obtained marketing approval, are recognized as In Process
Research & Development (IPR&D). IPR&D assets are only capitalized if they are deemed to
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enhance the intellectual property of Novartis and include items such as initial upfront and
milestone payments on licensed or acquired compounds. IPR&D is not amortized, but evaluated
for potential impairment on an annual basis or when facts and circumstances warrant. Any
impairment charge is recorded in the consolidated income statement under "Research &
Development". Once a project included in IPR&D has been successfully developed it is
transferred to the "Currently marketed product" category.
Sanofi14
Revenue arising from the sale of goods is presented in the income statement under Net
sales. Net sales comprise revenue from sales of pharmaceutical products, vaccines, and active
ingredients, net of sales returns, of customer incentives and discounts, and of certain sales-based
payments paid or payable to the healthcare authorities. Revenue is recognized when all of the
following conditions have been met: the risks and rewards of ownership have been transferred to
the customer; the Group no longer has effective control over the goods sold; the amount of
revenue and costs associated with the transaction can be measured reliably; and it is probable
that the economic benefits associated with the transaction will flow to the Group, in accordance
with IAS 18 (Revenue).
Intangible assets are initially measured at acquisition cost or production cost, including
any directly attributable costs of preparing the asset for its intended use, or (in the case of assets
acquired in a business combination) at fair value as at the date of the combination. They are
amortized on a straight line basis over their useful lives. The useful lives of intangible assets are
reviewed at each reporting date. The effect of any adjustment to useful lives is recognized
prospectively as a change of accounting estimate.

14
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Amortization of intangible assets is recognized in the income statement under
Amortization of intangibles with the exception of amortization of acquired or internallydeveloped software, which is recognized on the relevant line of the income statement according
to the purpose for which the software is used. The group does not own any intangible assets with
an indefinite useful life. Intangible assets are carried at cost less accumulated amortization and
accumulated impairment, if any, in accordance with IAS 36
GlaxoSmithKline15
Revenue is recognized in the income statement when goods or services are supplied or
made available to external customers against orders received, title and risk of loss is passed to
the customer, reliable estimates can be made of relevant deductions and all relevant obligations
have been fulfilled, such that the earnings process is regarded as being complete.
Intangible assets are stated at cost less provisions for amortization and impairments.
Licenses, patents, know-how and marketing rights separately acquired or acquired as part of a
business combination are amortized over their estimated useful lives, generally not exceeding 20
years, using the straight-line basis, from the time they are available for use. The estimated useful
lives for determining the amortization charge take into account patent lives, where applicable, as
well as the value obtained from periods of non-exclusivity. Asset lives are reviewed, and where
appropriate adjusted, annually. Contingent milestone payments are recognized at the point that
the contingent event becomes certain. Any development costs incurred by GlaxoSmithKline and
associated with acquired licenses, patents, and know-how or marketing rights are written off to
the income statement when incurred, unless the criteria for recognition of an internally generated
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intangible asset are met, usually when a regulatory filing has been made in a major market and
approval is considered highly probable.
Acquired brands are valued independently as part of the fair value of businesses acquired
from third parties where the brand has a value which is substantial and long-term and where the
brands either are contractual or legal in nature or can be sold separately from the rest of the
businesses acquired. Brands are amortized over their estimated useful lives of up to 20 years,
except where it is considered that the useful economic life is indefinite.
The costs of acquiring and developing computer software for internal use and internet
sites for external use are capitalized as intangible fixed assets where the software or site supports
a significant business system and the expenditure leads to the creation of a durable asset. ERP
systems software is amortized over seven to ten years and other computer software over three to
five years.
The US based pharmaceutical companies compared to the European pharmaceutical
companies show two difference consistent approaches to revenue recognition and intangible
assets. The following sections will elaborate on differences found using GAAP and IFRS.
Revenue Recognition
Revenue is a crucial number to users of financial statements in assessing an entity’s
financial performance and position. However, revenue recognition requirements in U.S.
generally accepted accounting principles (GAAP) differ from those in International Financial
Reporting Standards (IFRSs), and both sets of requirements need improvement. U.S. GAAP
comprises broad revenue recognition concepts and numerous requirements for particular
industries or transactions that can result in different accounting for economically similar
transactions. Although IFRSs have fewer requirements on revenue recognition, the two main

14

revenue recognition standards, IAS 18, Revenue, and IAS 11, Construction Contracts, can be
difficult to understand and apply.
Revenue recognition guidance under IFRS is provided principally by International
Accounting Standard (IAS) 18 Revenue. IAS 18 provides guidance on revenue recognition for
the provision of both goods and services. IAS11 also provides guidance but specifically in
relation to construction contracts and will usually not be applicable to most agreements
encountered in the pharmaceutical and biotechnology industries. Its requirements are, however,
applied by analogy through IAS 18.21.Under IFRS, revenue is recognized when it is probable
that future economic benefits will flow to the entity and those benefits can be measured reliably.
Revenue on sales of goods is only recognized when, inter alia, the significant risks and rewards
of ownership have been transferred to the buyer and the seller does not retain either control of
the goods, or continuing involvement, to the degree associated with ownership. For services,
evidence is required that a service has been delivered by requiring the seller to be able to
measure reliably the stage of completion of the transaction. In the pharmaceuticals industry it is
important to assess whether the selling entity has actually delivered something – either
transferring the risks and rewards of goods or other assets (e.g. licenses) or by providing service
to the buyer.16 Differences between US GAAP and IFRS under revenue recognition is as
follows:

Sale of Goods

16

US GAAP
SAB 104, Revenue
Recognition, requires
the risks and rewards
of ownership have
been transferred
(delivered).

IFRS
Revenue is
recognized when
risks and rewards of
ownership have
been transferred and

"International Financial Reporting Standards." PwC. July 2012
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Major Difference
Under GAAP,
revenue is not
recognized prior
to delivery. While,
IFRS may
recognize prior to

Research and
Development &
Services

the buyer has control delivery if risks
of the goods.
and rewards have
been transferred to
buyer.
Revenue may be
Revenue is not
recognized with
recognized until
long term
service is
accounting. Thus,
completed under
consideration for
GAAP. IFRS
stage of completion recognizes upfront
is needed to
revenue.
determine revenue
and costs reliably.

Service revenues is
recognized in
accordance to SAB
104.

Intangible Assets
Research & Development (R&D) activities are critical to the success of the life sciences
industry. Life sciences companies invest a significant amount of capital to research, discover and
clinically test new drug candidates in the hopes of generating future revenue. Accordingly, life
sciences companies must carefully consider whether any US GAAP-IFRS differences exist
relating to the accounting for intangible assets, including R&D costs. Some of the more
significant GAAP differences may include the accounting for internal development costs and (ii)
payments made to separately acquire or license intangible assets (for example, in a collaboration
arrangement).17 Some significant differences found in intangible assets can be seen below:
US GAAP
Costs are expensed as
it is incurred.

IFRS
Costs are capitalized
as long as specified
criteria is met.

Payments for rights
Payments (i.e.
Milestone or license) to a product not yet
received regulatory
approval is expensed.

Payments should be
capitalized as
intangible assets.

Development Costs

17
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Major Difference
Under IFRS,
development costs
will be recognized
over multiple periods,
where it does not
under GAAP
Intangibles may be
more accurately
stated under IFRS.

Advertising Costs

Revaluations

Payments for rights
to a product that has
received regulatory
approval is
capitalized.
Costs are either
expensed as incurred
or expense when it
occurs for the first
time.
Revaluation is not
allowed.

Costs are expensed as
it is incurred.

Revaluation to fair
value as an intangible
asset is a permitted
accounting policy.

IFRS allows for
prepayments to be
recognized as well, if
there is access to
goods.
Intangibles may be
more accurately
stated under IFRS.

Implementation
Revenue Recognition
Current plans suggest a consistency in revenue recognition regardless of the industry.
Organizations will be required to disclose quantitative information about contracts with
customers, including disaggregation of revenue, contract balances and changes in those balances,
remaining performance obligations and information about assets recognized from the costs to
obtain or fulfill contracts with customers; and qualitative information about revenue contracts
including significant judgments involved in applying the revenue guidance.
In addition, reporting organizations will be required to assess the goods or services
promised to a customer, identify performance obligations on the basis of whether the goods or
services are distinct, and recognize revenue when (or as) each performance obligation is
satisfied. Companies will be required to allocate the transaction price to each performance
obligation (or distinct good or service) in an amount that depicts the amount of consideration to
which the entity expects to be entitled in exchange for transferring the promised goods or
services to the customer. Variable consideration will be included in the transaction price to the

17

extent it is probable that a significant revenue reversal will not occur. Consideration can vary
because of discounts, rebates, refunds, credits, price concessions, incentives, performance
bonuses, penalties, or other similar items.
For public companies, the new guidance will be required for annual reporting periods
beginning after December 15, 2016, including interim reporting periods within that reporting
period. Early application is not permitted. For nonpublic companies, the new guidance will be
required for annual reporting periods beginning after December 15, 2017, and interim and annual
reporting periods after those reporting periods. A nonpublic entity may elect early application,
but no earlier than the effective date for public entities. For companies reporting under IFRS, the
new guidance will be required for reporting periods beginning on or after January 1, 2017. Early
application is permitted.18
With such changes, it is necessary for a delayed effective date because of the various
organizations that will be affected. These changes will also have a significant effect on other
areas of their financial statements that are tied to revenue recognition. Time is needed in order to
adjust to these changes.
Intangible Assets
FASB and IASB have no longer made intangible assets a priority, even though the
convergence was mentioned in the “Memorandum of Understanding” (MOU) in 2006.
Nonetheless, it was mentioned in the 2008 MOU that there is a possibility for a new project to
eliminate differences in the accounting for research and development costs. Thoughts are
formulated that the IAS 38 will be adopted in the future.

18

"Revenue Recognition." FASB, Financial Accounting Standards Board.
<http://www.fasb.org/jsp/FASB/Page/BridgePage%26cid%3D1351027207987#section_6>.
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In March 2009, the FASB’s Emerging Issues Task Force tentatively concluded in EITF
09-2 Research and Development Assets Acquired in an Asset Acquisition that research and
development assets acquired in an asset acquisition should be capitalized. While the Task Force
is in the early stages of its deliberations on the Issue, it could result in convergence for certain
aspects of accounting for intangible assets that are significant for life sciences companies (for
example, payments to acquire or in-license intangible assets, such as through R&D collaboration
arrangements, would be capitalized, which is consistent with the accounting under IFRS).19
Conclusion
In summary, the accounting challenges in a pharmaceutical industry continue to be
centered around revenue recognition (upfront vs. deferral), accounting for research and
development (capitalize vs. expense) and intangible assets (amortize and carry forward vs.
impair). Adoption of IFRS around the world is expected to introduce homogeneity in accounting
practices and permit international comparability and thereby accelerate cross border
transactions.20
As a result many benefits will be seen. By converging the US GAAP and IFRS,
businesses will be able to present financial statements among foreign relations and it will allow
for easier comparisons. Also, tying back to globalization, as many companies have subsidiaries
in other countries, it allows for a consistent accounting standard to be used worldwide, instead of
confusion within the company. To accommodate for the impact the changes may have, a steady
gradual convergence is necessary. Nonetheless, the change will not be taken lightly by upper
management who are thinking about cost effectiveness. It will also impact investors, stock
markets, accounting professionals, and the accounting standard rule setters.
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"US GAAP vs IFRS: The Basics: Life Science." EY. June 2009
"Accounting and Auditing Update" KPMG. July 2010.
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The program of converging accounting standards between the Financial Accounting
Standards Board and the International Accounting Standards Board is nearing an end after more
than a decade. Along the way there have been some bumps and differences in view between
FASB and IASB, but this unique standard-setting partnership has resulted in converged or
substantially converged standards on a number of major subjects, including accounting for
business combinations, employee stock compensation, fair-value measurements, and segment
reporting.21

21

Herz, Robert. "End of Convergence Brings Challenges and Opportunities." Compliance Week. 27 Aug. 2013.
<http://www.complianceweek.com/end-of-convergence-brings-challenges-and-opportunities/article/307946/>.
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